Targeted lipid nanoparticles to prevent trans-placental passage in the ex vivo human placental cotyledon perfusion model
Open Access
- 14 October 2024
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (6) , 1985-1993
Abstract
Medication use during pregnancy poses risks to both the mother and the fetus. These risks include an elevated potential for fetotoxicity due to placental drug transport. Nanomedicines offer a promising solution by potentially preventing trans-placental passage. Targeted nanomedicines could enhance safety and efficacy in treating maternal or placental pathophysiology. Our study investigates placental transfer kinetics of targeted lipid nanoparticles (LNPs) in an ex vivo human placenta cotyledon perfusion model. We collected human placentas for dual-side ex vivo placental perfusions. Targeted LNPs with a fluorescence tag were introduced into the maternal circuit of each placenta. To establish if there was trans-placental passage of LNPs to the fetal circuit, we collected samples from maternal and fetal circuits throughout the six hours of the perfusion. We determined the fluorescence signal using a multi-mode microplate reader and Multiphoton microscopy to localize the LNPs in the placenta tissue. Data from perfused placenta tissue showed no significant transfer of the fluorescently labeled LNPs across the placental barrier to the fetal circuit. Localization of targeted LNPs in tissue samples is mainly observed in the maternal blood space of the placenta. Our results suggest that targeted LNPs present a promising strategic approach to prevent trans-placental passage to the fetus. Our future perspectives involve investigating the efficacy of targeted LNPs as well as loading targeted LNPs with nucleic acid-based therapeutics to investigate their therapeutic potential. Graphical AbstractKeywords
All Related Versions
Funding Information
- ZonMw (09120011910045)
This publication has 38 references indexed in Scilit:
- The immunostimulatory nature of mRNA lipid nanoparticlesAdvanced Drug Delivery Reviews, 2024
- Nanomedicines: An approach to treat placental insufficiency and the current challengesJournal of Controlled Release, 2023
- Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1Molecular Therapy Nucleic Acids, 2022
- Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion ExperimentsClinical Pharmacokinetics, 2022
- Research on nanoparticles in human perfused placenta: State of the art and perspectivesPlacenta, 2021
- Megalin-targeting liposomes for placental drug deliveryJournal of Controlled Release, 2020
- Nanoparticle mediated increased insulin-like growth factor 1 expression enhances human placenta syncytium functionPlacenta, 2020
- Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused PlacentaClinical Pharmacology & Therapeutics, 2020
- A head-to-head comparison of conjugation methods for VHHs: Random maleimide-thiol coupling versus controlled click chemistryInternational Journal of Pharmaceutics: X, 2019
- Transfer across the perfused human placenta of antipyrine, sodium, and leucineAmerican Journal of Obstetrics and Gynecology, 1972